Navigation Links
AMDL, Inc. Closes Private Placement of Convertible Notes
Date:9/16/2008

TUSTIN, Calif., Sept. 16 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with major operations in China and the US, announced today the successful closing and terms of a $2,510,000 private placement offering of 10% convertible notes. The placement agents for the offering were Jesup & Lamont Securities Corporation and Dawson James Securities, Inc.

Mr. Gary Dreher, President and CEO of AMDL, Inc., said, "This financing strengthens our cash position and allows us to accelerate key business initiatives. We appreciate the financial support from our investors and their vote of confidence in AMDL's China and US-led operations."

AMDL sold $2,510,000 of 10% convertible notes at par value. The notes mature at the earlier of 12 months from the completion of a registered follow-on public offering or 24 months after issuance. The notes will be repaid either at maturity in cash equal to 150% of the principal amount of the notes plus an amount equivalent to 10% per annum interest, or upon forced mandatory conversion into shares of the Company's common stock in the event of a public offering of at least $25 million in gross proceeds to AMDL. At any time after February 15, 2009, the holders of the notes have the right to convert the entire principal and interest due thereon into common stock of the Company. The conversion price will be at a discount of fifty percent (50%) to the: (i) price of the Company's common stock on the closing of the public offering; or (ii) common stock on February 15, 2009; provided, however, in no event shall the conversion price be less than $1.20 per share. In the event of a voluntary conversion,
'/>"/>

SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
2. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
3. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
4. World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round
5. Pathwork Diagnostics Closes $20M Financing
6. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
7. PAREXEL Closes the Acquisition of ClinPhone
8. Cytochroma Closes $45 Million Series C Financing
9. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
10. AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
11. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Gamida Cell announced today,a feasibility study evaluating the ... therapy product which combines technology from Weill,Cornell Medical ... potential to,treat inherited anemias such as Cooley,s Anemia. ... developing a series of technologies to expand, ex ...
(Date:12/2/2009)... Dairy, Inc.,("Emerald Dairy" or the "Company") (OTC Bulletin Board: ... formula, milk powder and,soybean products in China, today announced ... of US Food & Drink Executive, a quarterly magazine ... and beverage industry. , The ...
(Date:12/2/2009)... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ... company focused on endocrine therapy and oncology, today ... (FDA) has granted Fast Track designation for the ... the treatment of relapsed/refractory multiple myeloma. Keryx Biopharmaceuticals, ...
(Date:12/2/2009)... Scientist, a leading scientific magazine covering the life sciences, ranked ... 10 Innovations of 2009. , ... ... camera from Photometrics ®, a designer and manufacturer ...
Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
... Named President of Europe/Middle East/Africa and Canada -, ... division of Wyeth (NYSE: WYE ), announced ... - Europe/Middle East/Africa,and Canada, effective immediately. In this ... Mahady, President - Wyeth Pharmaceuticals, and Senior Vice,President, ...
... to take a more proactive approach ... assessment of drug safety information, HYDERABAD, India ... Services Ltd. (NYSE: SAY ), a leading ... that it has,formed an alliance with Sciformix Corporation, ...
... ROCKVILLE, Md., June 26 Pinnacle Biologics, a ... announced,that it has entered into a preferred stock ... has acquired certain,unspecified number of preferred stock shares ... were not disclosed., Pinnacle Biologics owns the ...
Other Biology Technology:Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 2Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 3Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 4
(Date:12/2/2009)... an increased risk of developing lung cancer in adulthood, even ... are published in Cancer Epidemiology, Biomarkers & Prevention , ... part of a special tobacco focus in the December issue. ... be diagnosed with lung cancer; more than 159,000 will die ...
(Date:12/2/2009)... that people who smoke cigarettes over a long period ... cancer, even after adjusting for other risk factors. ... or to quit as soon as possible," said senior ... epidemiology and surveillance research at the American Cancer Society. ...
(Date:12/2/2009)... smoke their first cigarette within minutes after waking up have ... processed by the body, than those who wait to smoke, ... , "Since cotinine levels appear to reflect the risk of ... after waking may be especially at risk for lung cancer," ...
Breaking Biology News(10 mins):Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Cigarette smoking increases colorectal cancer risk 2Increased nicotine levels detected in those who light-up earlier 2Researchers effectively treat tumors with use of nanotubes 53492 1Researchers effectively treat tumors with use of nanotubes 53492 2Researchers effectively treat tumors with use of nanotubes 53492 3Why anorexic patients cling to their eating disorder 53489 1Why anorexic patients cling to their eating disorder 53489 2Scientists open doors to diagnosis of emphysema 9456 1Scientists open doors to diagnosis of emphysema 9456 2
... Researchers at the University of Illinois at Urbana-Champaign have ... other drugs in saliva, urine or blood serum. The ... be packaged in user-friendly kits similar to those used ... work with lead (Pb) sensors, we constructed colorimetric sensors ...
... a new study published online this week in the open ... present a high resolution genetic map for the mouse genome--one ... that for humans. , To create this map, they ... stock (HS) and the other of recombinant inbred lines (RI). ...
... million people in the world, including 25.8 million in Sub-Saharan ... of HIV-1, responsible for the AIDS pandemic, has been stimulating ... the team of Martine Peeters, director of research at IRD, ... 145 jointly involving the IRD and the University of Montpellier ...
Other Biology News:Scientists design simple dipstick test for cocaine, other drugs 2Mapping the mouse genome 2Wild gorillas carriers of a SIV virus close to the AIDS virus 2
... GenePix Pro is the industry standard ... unique combination of imaging and analysis tools, ... use. GenePix Pro is included with every ... images from third-party scanners and all types ...
... ideal instrument for budget-conscious labs that want to ... Get Applied Biosystems proven PCR performance at ... without sacrificing results. Enhance productivity with ... Can Afford The Applied Biosystems 2720 ...
... a wide variety of purity levels, scales and ... Purity: IG(>50%), >70%, >80% and >95% ... Length: Up to 120 residues ... acids, MAPs, KLH/BSA conjugation, and much more. ...
... The AquaMax DW4 liquid handling system ... thorough washing all in one instrument. The ... for dispensing and plate washing96-, 384- and ... microplate washing. AquaMax DW4 has been optimized ...
Biology Products: